Form 8-K - Current report:
SEC Accession No. 0001193125-25-281676
Filing Date
2025-11-14
Accepted
2025-11-14 08:16:47
Documents
17
Period of Report
2025-11-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d59851d8k.htm   iXBRL 8-K 55246
2 EX-2.1 d59851dex21.htm EX-2.1 535510
3 EX-10.1 d59851dex101.htm EX-10.1 54923
4 EX-99.1 d59851dex991.htm EX-99.1 28907
8 GRAPHIC g46394dsp1a.jpg GRAPHIC 7168
9 GRAPHIC g46394dsp1b.jpg GRAPHIC 6990
  Complete submission text file 0001193125-25-281676.txt   975632

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20251113.xsd EX-101.SCH 2834
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20251113_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20251113_pre.xml EX-101.PRE 11250
19 EXTRACTED XBRL INSTANCE DOCUMENT d59851d8k_htm.xml XML 3645
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 251481391
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)